Penumbra Q3 revenue $190.1M (+26%), swings to operating profit; raises FY guidance

Penumbra Inc

2021-Q3 EPS reported $0.80 revenue$543,579,000

Revenue $190.1M, +25.8% YoY (+25.6% constant currency); US 71%, international 29%.
Vascular segment $105.5M (+40.3%); Neuro segment $84.7M (+11.5%).
Gross margin 63.1% vs 60.2%; operating income $8.8M vs loss of $20.2M a year ago.
Full-year 2021 revenue guidance raised to $735M-$740M from prior $720M-$730M.
R&D expense fell to $16.7M from $34.9M; SG&A rose to $94.4M from $76.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.